{
    "pmcid": "11209230",
    "qa_pairs": {
        "How have engineered multivalent forms of nanobodies, such as the trivalent and bispecific Nb15-NbH-Nb15, demonstrated their efficacy?": [
            "They offer protection against SARS-CoV-2 infection in transgenic hACE2 mice for both preventive and therapeutic uses.",
            "They have shown increased solubility and stability in vitro compared to monovalent forms.",
            "They provide enhanced binding affinity to the RBD of SARS-CoV-2 in cell culture assays.",
            "They have demonstrated the ability to neutralize SARS-CoV-2 in human clinical trials."
        ],
        "What are the advantages of nanobodies over conventional monoclonal antibodies in terms of size and structure?": [
            "Nanobodies are smaller, allowing for better epitope accessibility, superior solubility, and stability.",
            "Nanobodies have a larger size, which enhances their binding strength and stability.",
            "Nanobodies have a similar size to monoclonal antibodies but offer better solubility.",
            "Nanobodies are larger, making them more stable and easier to produce."
        ],
        "What is a limitation of nanobodies due to the lack of an Fc fragment, and how might this be addressed?": [
            "The lack of an Fc fragment limits immune effector recruitment, which could be addressed by molecular modification or coupling with other molecules.",
            "The lack of an Fc fragment reduces binding affinity, which could be addressed by increasing the nanobody size.",
            "The lack of an Fc fragment limits tissue penetration, which could be addressed by altering the nanobody structure.",
            "The lack of an Fc fragment decreases solubility, which could be addressed by chemical stabilization."
        ],
        "What is the significance of shark-derived nanobodies like S2A9 in the context of SARS-CoV-2?": [
            "They target the S2 stem helix region and show broad neutralization capability against pseudotyped SARS-CoV-2 VOCs and Omicron subvariants.",
            "They bind to the RBD and are effective against all known SARS-CoV-2 variants.",
            "They are larger than camelid-derived nanobodies, offering enhanced stability and solubility.",
            "They have a unique structure that allows them to neutralize SARS-CoV-2 without binding to the spike protein."
        ],
        "Which specific nanobody binds to a conserved epitope on the bottom of the RBD, providing protection against Omicron and Delta infections?": [
            "Nanobody 3-2A2-4",
            "Nanobody Nb70",
            "Nanobody 1-2C7",
            "Nanobody S2A9"
        ]
    }
}